LTRN: Lantern Pharma, Inc.
About
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Current Value
$3.001 Year Return
Current Value
$3.001 Year Return
Key Details
Market Cap
$33.22M
P/E Ratio
-1.74
1Y Stock Return
-22.61%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.2
Strategies that include LTRN
Stock's related to LTRN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OSPN | 31.74% | $644.33M | +69.09% | 0.00% |
| PUBM | 28.61% | $739.82M | -2.82% | 0.00% |
| SPCE | 28.57% | $196.64M | -84.01% | 0.00% |
| ML | 27.65% | $922.62M | +146.62% | 0.00% |
| AER | 26.19% | $19.38B | +43.87% | 0.78% |
| ACMR | 26.16% | $1.15B | +5.14% | 0.00% |
| UPST | 26.00% | $6.49B | +199.03% | 0.00% |
| ALAB | 25.91% | $15.10B | +164.39% | 0.00% |
| LMB | 25.28% | $1.12B | +157.63% | 0.00% |
| CTRN | 25.26% | $153.27M | -29.99% | 0.00% |
| BKD | 25.03% | $1.04B | -2.44% | 0.00% |
| DQ | 24.96% | $1.20B | -29.81% | 0.00% |
| SEER | 24.67% | $134.44M | +40.74% | 0.00% |
| TDG | 24.52% | $70.32B | +35.98% | 0.00% |
| HNST | 24.51% | $739.03M | +360.38% | 0.00% |
| AFRM | 24.46% | $20.09B | +155.53% | 0.00% |
| OPEN | 24.45% | $1.14B | -31.62% | 0.00% |
| COIN | 24.41% | $81.26B | +207.68% | 0.00% |
| CRON | 23.94% | $776.06M | 0.00% | 0.00% |
| GBIO | 23.93% | $92.84M | +20.87% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CARM | -0.01% | $36.20M | -64.46% | 0.00% |
| USAC | 0.02% | $2.76B | -3.87% | 8.93% |
| UUU | -0.02% | $4.97M | -41.89% | 0.00% |
| GTY | 0.03% | $1.81B | +13.14% | 5.51% |
| QXO | 0.03% | $6.51B | -35.95% | 0.00% |
| AEP | 0.04% | $51.50B | +23.91% | 3.71% |
| FCN | -0.06% | $7.10B | -10.74% | 0.00% |
| WRB | -0.06% | $22.94B | +29.98% | 0.69% |
| INSM | -0.06% | $13.19B | +202.50% | 0.00% |
| CODX | 0.07% | $34.16M | -25.17% | 0.00% |
| CMS | -0.09% | $20.49B | +20.66% | 3.01% |
| ABBV | -0.09% | $294.35B | +20.07% | 3.72% |
| VNOM | -0.10% | $5.48B | +79.62% | 3.35% |
| EXLS | -0.11% | $7.12B | +59.40% | 0.00% |
| TVTX | -0.12% | $1.51B | +207.79% | 0.00% |
| IEP | 0.15% | $5.70B | -31.12% | 31.39% |
| EVRI | -0.16% | $1.15B | +23.27% | 0.00% |
| XBIO | 0.17% | $6.01M | +21.36% | 0.00% |
| SRRK | -0.17% | $2.61B | +134.91% | 0.00% |
| PKG | 0.19% | $21.40B | +55.25% | 2.10% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMLX | -24.45% | $357.82M | -58.70% | 0.00% |
| PHI | -15.68% | $4.83B | -1.80% | 7.58% |
| AMPY | -13.84% | $260.89M | +7.01% | 0.00% |
| VZIO | -13.56% | $2.29B | +67.76% | 0.00% |
| IP | -12.50% | $20.09B | +78.02% | 3.20% |
| HUSA | -12.04% | $16.69M | -11.56% | 0.00% |
| SJM | -11.96% | $11.91B | -0.25% | 3.82% |
| DKL | -11.80% | $2.03B | -18.84% | 10.94% |
| BDX | -11.65% | $64.35B | -5.72% | 1.71% |
| CYD | -11.62% | $364.46M | -2.94% | 4.26% |
| WOW | -11.50% | $434.90M | +18.48% | 0.00% |
| VZ | -11.21% | $176.51B | +12.56% | 6.37% |
| TMUS | -11.16% | $270.63B | +56.92% | 0.83% |
| PRT | -10.92% | $48.72M | -16.56% | 10.33% |
| G | -10.80% | $7.83B | +31.86% | 1.34% |
| VSCO | -10.20% | $2.85B | +71.64% | 0.00% |
| CRC | -9.86% | $5.29B | +11.76% | 2.28% |
| PHG | -9.71% | $24.26B | +27.17% | 0.00% |
| EDR | -9.46% | $9.01B | +19.26% | 0.82% |
| CQP | -9.45% | $25.90B | -6.77% | 5.96% |
ETF's related to LTRN
News
Yahoo
DALLAS, November 19, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs).
Yahoo
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reported third quarter 2024 financial results and achievements in a November 7 th , 2024 press release . Since our previous report, the company has been granted three additional rare pediatric disease designations for LP-184, and Fast Track designation for glioblastoma. It has also announced
Yahoo
Lantern Pharma Inc (LTRN) showcases significant clinical progress and strategic expansions, despite increased net loss and R&D expenses.
SeekingAlpha
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsPanna Sharma - President and CEODavid...
Yahoo
DALLAS, November 07, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024.
Yahoo
DALLAS, November 05, 2024--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board ("SAB") to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight’s management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and br
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.